ABUS at a glance
Arbutus Biopharma Corp (ABUS, SEC CIK 1447028) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Arbutus Biopharma Corp (ABUS) shares worth $288.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.1M
- +128.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $288.1M · +2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include clinical development and regulatory approval uncertainty
- Carried-forward risks include dependence on partnered product candidates and licensing arrangements
- Carried-forward risks include liquidity needs and potential financing requirements
Management Discussion & Analysis
- Q3 revenue $13.0M, down $0.2M YoY, reflecting lower ONPATTRO royalty revenue
- Q3 operating loss $10.5M vs $8.7M loss YoY, operating margin -80.5% vs -67.2%
- Best program: IM-PROVE II, 53% (33/62) achieved functional cure or remained off NA therapy
- Cash and equivalents $264.2M at September 30, up from $18.0M; operating cash flow $225.7M
- Capital deployment: $230M share repurchase settled October 5; AB-101 development resumed after FDA clinical hold lifted
AI summary of the ABUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Updated corporate presentation posted November 12, 2026
- Investor relevance depends on substantive pipeline, clinical, financing or strategic updates in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q4 2026 corporate presentation highlights imdusiran as the lead cHBV asset, with potential Phase 2b development plans under evaluation
- Cash and equivalents of $104.6M as of October 31, 2026, supporting near-term clinical development
Item 2.02: Results of Operations and Financial Condition
- Third-quarter financial results for period ended September 30, 2026 announced
- Investor-relevant details, including revenue, expenses and cash position, contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Cash and marketable securities $337.5M at September 30, up from $91.5M, strengthening funding for clinical programs
- $230M tender offer repurchased 46M shares at $5.00, approximately 23% of outstanding shares, materially reducing share count
Item 8.01: Other Events
- FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor
- Clinical development can resume, reducing a key regulatory obstacle
Item EX-99.1: Item EX-99.1
- FDA clinical hold lifted for AB-101, restoring U.S. clinical development eligibility
- AB-101 Phase 1a/1b data showed generally good tolerability and high receptor occupancy in seven cHBV patients
AI summaries of ABUS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABUS
Don't miss the next ABUS filing
- Alerts as it files. A push when ABUS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABUS, by share count.
- Ask anything. An AI agent that reads every ABUS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Beardsley Robert A | D | Oct 1, 2026 | 17,948 | $5.00 |
| Roivant Sciences Ltd. | D | Oct 1, 2026 | 8,967,383 | $5.00 |
| Androski Lindsay | D | Oct 1, 2026 | 24,655 | $5.00 |
| Nguyen Tuan | D | Oct 1, 2026 | 48,081 | $5.00 |
| Sawhney Roger | D | Oct 1, 2026 | 17,142 | $5.00 |
| Androski Lindsay | M | Sep 18, 2026 | 116,408 | $3.20 |
| Nguyen Tuan | M | Sep 18, 2026 | 27,475 | $4.39 |
| Nguyen Tuan | M | Sep 18, 2026 | 265,625 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.2M | $14.1M |
| Operating Income | - | -$76.3M | -$38.2M |
| Net Income | -$72.8M | -$69.9M | -$33.5M |
| Op. Margin | - | -1236.7% | -271.0% |
| Net Margin | - | -1133.0% | -237.9% |
| Balance Sheet | |||
| Total Assets | $144.4M | $131.7M | $94.6M |
| Equity | - | $97.4M | $76.6M |
| ROE | - | -71.8% | -43.7% |
| Per Share | |||
| EPS | $-0.44 | $-0.38 | $-0.17 |
| Cash Flow | |||
| Operating CF | - | -$64.8M | -$39.6M |
| CapEx | $1.0M | $182K | $0 |
Source: XBRL data in Arbutus Biopharma Corp (ABUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ABUS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $288.1M |
| Q2 2026 | 25 | $281.7M |
| Q1 2026 | 24 | $274.4M |
| Q4 2025 | 20 | $297.6M |
| Q3 2025 | 22 | $266.6M |
| Q2 2025 | 26 | $181.8M |
| Q1 2025 | 23 | $149.9M |
| Q4 2024 | 18 | $55.3M |
- D.E. Shaw & Co+783.1K (+205%)
- BlackRock+749.4K (+5%)
- Morgan Stanley+677.7K (+4%)
- Prudential Financial+147.9K (+561%)
- AQR Capital Management+26.5K (+83%)
- Bank of America Corp−1.34M (-51%)
- Goldman Sachs Group−926.3K (-26%)
- State Street Corp−787.7K (-10%)
- Citadel Advisors LLC−322.4K (-80%)
- Citigroup−285.4K (-32%)
- FMR LLC (Fidelity)−267.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABUS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| SC 13G | Sep 4, 2026 | - | - | |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 10-K | Mar 23, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ABUS SEC filings: frequently asked questions
Which institutions hold ABUS stock?
As of September 30, 2026, the largest Arbutus Biopharma Corp (ABUS) holders among the 13F filers tracked by SignalX were Morgan Stanley ($87.8 million), BlackRock ($69.4 million), State Street Corp ($33.9 million), Vanguard Capital Management LLC ($33.4 million), Millennium Management ($14.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABUS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17. The figures come from the XBRL data in the 10-K.
What did ABUS report in its latest 8-K?
Arbutus Biopharma Corp (ABUS) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). Updated corporate presentation posted November 12, 2026.
What are the latest ABUS SEC filings?
Arbutus Biopharma Corp (ABUS) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 7, 2026.
What is ABUS's SEC CIK number?
Arbutus Biopharma Corp (ABUS)'s SEC Central Index Key (CIK) is 1447028. EDGAR lists every ABUS filing under that number.
Ask anything about ABUS
The research agent reads ABUS's filings, financials, insider trades and 13F holders, then answers with sources.